GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cidara Therapeutics Inc (NAS:CDTX) » Definitions » Cyclically Adjusted Price-to-FCF

CDTX (Cidara Therapeutics) Cyclically Adjusted Price-to-FCF : (As of Jun. 02, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Cidara Therapeutics Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cidara Therapeutics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Cidara Therapeutics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cidara Therapeutics Cyclically Adjusted Price-to-FCF Chart

Cidara Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cidara Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cidara Therapeutics's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Cidara Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cidara Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cidara Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Cidara Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


;
;

Cidara Therapeutics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Cidara Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Cidara Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-1.548/134.9266*134.9266
=-1.548

Current CPI (Mar. 2025) = 134.9266.

Cidara Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -10.934 100.684 -14.653
201509 -11.482 100.392 -15.432
201512 -10.450 99.792 -14.129
201603 -15.855 100.470 -21.292
201606 -13.883 101.688 -18.421
201609 -11.145 101.861 -14.763
201612 -14.474 101.863 -19.172
201703 -17.421 102.862 -22.852
201706 -14.360 103.349 -18.748
201709 -16.440 104.136 -21.301
201712 -9.868 104.011 -12.801
201803 -14.118 105.290 -18.092
201806 -13.184 106.317 -16.732
201809 -9.290 106.507 -11.769
201812 -8.923 105.998 -11.358
201903 -12.022 107.251 -15.124
201906 -8.975 108.070 -11.205
201909 8.351 108.329 10.401
201912 -7.145 108.420 -8.892
202003 -8.011 108.902 -9.925
202006 -6.918 108.767 -8.582
202009 -6.545 109.815 -8.042
202012 -5.038 109.897 -6.185
202103 -0.769 111.754 -0.928
202106 1.154 114.631 1.358
202109 -4.838 115.734 -5.640
202112 -4.615 117.630 -5.294
202203 -6.954 121.301 -7.735
202206 -3.428 125.017 -3.700
202209 6.312 125.227 6.801
202212 -5.843 125.222 -6.296
202303 -2.172 127.348 -2.301
202306 0.603 128.729 0.632
202309 -0.390 129.860 -0.405
202312 -2.850 129.419 -2.971
202403 -1.469 131.776 -1.504
202406 -22.739 132.554 -23.146
202409 -5.636 133.029 -5.716
202412 -2.687 133.157 -2.723
202503 -1.548 134.927 -1.548

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cidara Therapeutics  (NAS:CDTX) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Cidara Therapeutics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Cidara Therapeutics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Cidara Therapeutics Business Description

Traded in Other Exchanges
Address
6310 Nancy Ridge Drive, Suite 101, San Diego, CA, USA, 92121
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
Executives
Leslie Tari officer: Chief Scientific Officer C/O CIDARA THERAPEUTICS, INC., 6310 NANCY RIDGE DR SUITE 101, SAN DIEGO CA 92121
Shane Ward officer: CHIEF LEGAL OFFICER C/O VERSARTIS, INC., 4200 BOHANNON DR., SUITE 250, MENLO PARK CA 94025
Taylor Sandison officer: Chief Medical Officer 6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Jeffrey Stein director, officer: President & CEO 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Preetam Shah officer: CFO & CBO C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019
Paul Daruwala officer: Chief Medical Officer 6310 NANCY RIDGE DR, SAN DIEGO CA 92121
Brady Johnson officer: Dir. of Finance & Controller 6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Timothy R Franson director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Carin Canale-theakston director C/O CIDARA THERAPEUTICS, INC., 6310 NANCY RIDGE DR STE 101 CA 92121
Bonnie L Bassler director REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
James E. Levine officer: Chief Financial Officer 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Theodore R Schroeder director 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Chrysa Mineo director 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
David L Gollaher director 6310 NANCY RIDGE DR, SAN DIEGO CA 92121
Daniel D Burgess director C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121